For Further Information Contact: Sandra M. Peay, Contract Representative, or Renee Hallman, Case Management Assistant, Federal Trade Commission, Premerger Notification Office, Bureau of competition, Room H– 303, Washington, DC 20580, (202) 326– 3100.

By direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 05-8618 Filed 4-29-05; 8:45 am] BILLING CODE 6750-01-M

OFFICE OF GOVERNMENT ETHICS

Review of Criminal Conflict of Interest Statutes; Opportunity for Comment

AGENCY: Office of Government Ethics (OGE).

ACTION: Notice.

SUMMARY: The Office of Government Ethics is conducting a review, pursuant to the Intelligence Reform and Terrorism Prevention Act of 2004, of the criminal conflict of interest statutes relating to executive branch employment. This notice provides the public and agencies an opportunity to comment.

DATES: Any comments from the public and the agencies must be received by June 20, 2005.

ADDRESSES: You may submit comments to OGE by any of the following methods:

• *E-mail: usoge@oge.gov.* For E-mail messages, the subject line should include the following reference: "Comments Regarding Criminal Conflict of Interest Statutes Review."

• Fax: (202) 482–9237.

• *Mail, Hand Delivery or Courier:* Office of Government Ethics, Suite 500, 1201 New York Avenue, NW., Washington, DC 20005–3917, Attention: Stuart D. Rick, Deputy General Counsel.

FOR FURTHER INFORMATION CONTACT: Stuart D. Rick, Deputy General Counsel, Office of Government Ethics, telephone: (202) 482–9300; TDD: (202) 482–9293; FAX: (202) 482–9237.

SUPPLEMENTARY INFORMATION: Section 8403(d) of the Intelligence Reform and Terrorism Prevention Act of 2004, Public Law 108–458 (December 17, 2004), directs the Office of Government Ethics, in consultation with the Department of Justice, to conduct a comprehensive review of the conflict of interest laws relating to executive branch employment. By December 17, 2005, OGE must submit a report to the President and pertinent Congressional committees reflecting its findings. OGE

will review 18 U.S.C. 203, 205, 207, 208, and 209, and make recommendations for appropriate revisions that will both enhance Government effectiveness and protect the integrity of Government operations. To assist us in our review, OGE is seeking the views of the public and Federal agencies concerning the need for improvements to the criminal conflict of interest statutes. Interested persons may submit written comments to OGE by June 20, 2005.

Approved: April 27, 2005.

Marilyn L. Glynn,

Acting Director, Office of Government Ethics. [FR Doc. 05–8691 Filed 4–29–05; 8:45 am] BILLING CODE 6345–02–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Meeting of the Advisory Committee on Blood Safety and Availability

AGENCY: Department of Health and Human Services, Office of the Secretary. **ACTION:** Notice.

SUMMARY: As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (DHHS) is hereby giving notice that the Advisory Committee on Blood Safety and Availability (ACBSA) will hold a meeting. This meeting is open to the public.

DATES: The meeting will be held on Monday, May 16, 2005 and Tuesday, May 17, 2005 from 9 a.m. to 5 p.m.

ADDRESSES: The meeting will be held at the Bethesda North Marriott Hotel and Conference Center, 5701 Marinelli Road, North Bethesda, Maryland 20852.

FOR FURTHER INFORMATION CONTACT: Jerry A. Holmberg, Ph.D., Executive Secretary, Advisory Committee on Blood Safety and Availability, Office of Public Health and Science, Department of Health and Human Services, 1101 Wootton Parkway, Suite 250, Rockville, MD 20852, (301) 443–2331, fax (301) 443–4788, e-mail

jholmberg@osophs.dhhs.gov.

SUPPLEMENTARY INFORMATION: DHHS is responsible for carrying out research in health fields including diseases involving blood and blood products, and for issuing and enforcing regulations concerning the collection, preparation, and distribution of blood and blood products, and regulations related to the transmission of communicable diseases. The ACBSA advises, assists, consults with, and makes policy recommendations to the Secretary and the Assistant Secretary for Health regarding these broad responsibilities.

The Advisory Committee on Blood Safety and Availability will meet to review progress and solicit additional comments from the Committee regarding numerous recommendations made over the past year. Specifically, the Committee will hear updates and discuss previous recommendations on potential studies to standardize, validate, and determine the predictive value of bacterial testing with the intent to extend the dating of platelet products from five to seven days and the possible pre-storage pooling of whole blood derived platelets. In addition, the Committee will be asked to discuss/ comment on strategies for addressing infectious agents (known or emerging) that potentially could affect the blood supply.

Public attendance at the meeting is limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the designated contact person.

Members of the public will have the opportunity to provide comments at the meeting. Public comments will be limited to five minutes per speaker. Anyone planning to comment is encouraged to contact the Executive Secretary at his/her earliest convenience. Individuals who wish to have material distributed to the Committee for review and discussion are asked to provide at a minimum 30 copies for this purpose. If the requested amount of copies cannot be provided, a copy of the document should be provided to the Executive Secretary for duplication purposes no later than May 11, 2005.

Dated: April 26, 2005.

Jerry A. Holmberg,

Executive Secretary, Advisory Committee on Blood Safety and Availability.

[FR Doc. 05–8669 Filed 4–29–05; 8:45 am] BILLING CODE 4150–41–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

National Advisory Council for Healthcare Research and Quality: Request for Nominations for Public Members

AGENCY: Agency for Healthcare Research and Quality, HHS.